Application and future prospects of bispecific antibodies in the treatment of colorectal cancer
Over the past decade, the incidence of colorectal cancer (CRC) has continued to rise, imposing a substantial disease burden on both patients and society. Improvements in treatment strategies—including surgery, chemotherapy, targeted therapy, and immunotherapy—have significantly improved clinical outcomes. Immunotherapy, particularly immune checkpoint inhibitors, has shown promising efficacy in rectal cancer studies. Nevertheless, multiple CRC subtypes are still hindered by an immunosuppressive tumor microenvironment, the development of therapeutic resistance, and low response rates to immunotherapy, collectively limiting further gains in clinical benefit. As an emerging therapeutic modality, bispecific antibodies (BsAbs) possess two binding specificities, enabling them to bind simultaneously to the same or different antigens, thereby generating multifaceted anti-tumor effects. Therefore, BsAbs can help overcome treatment resistance and potentiate antitumor immune responses. To date, numerous BsAbs have been used in clinical trials to assess their safety and efficacy across diverse CRC subtypes. This review summarizes the main classes of BsAbs used for CRC treatment, focusing on their mechanisms of action and recent advances in clinical research. We further discuss existing challenges for BsAbs and the potential strategies.
Authors
- Kai Long
- Qipeng Yao
- Yihua Zeng
- Chao Chen
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fimmu.2026.1995473
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00